The bispecific bridges EGFR on tumor cells and CD28 on T cells to provide localized CD28 costimulation, enhancing TCR-dependent T‑cell killing (e.g., perforin/granzyme, Fas/FasL) of EGFR-positive cells; the drug itself is not directly cytotoxic and does not redirect via CD3.